{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"ORR (Complete Response \\[CR\\] plus Partial Response \\[PR\\]) to induction chemotherapy with platinum and docetaxel plus AT-101 following one and/or two cycles in patients with advanced laryngeal cancer.","groups":[{"description":"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.\n\nPatients underwent induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).\n\n(AT-101 Arm) Days #1-3: Patients received AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy.\n\nAT-101: Patients received AT-101 40 mg orally two times a day.\n\nCisplatin: Cisplatin 100 mg/m2\n\nCarboplatin: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg","id":"OG000","title":"Platinum/Docetaxal + AT-101"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This outcome measure only applies to those subjects treated with induction chemotherapy with platinum and docetaxel plus AT-101 and therefore only one arm is being reported","reportingStatus":"POSTED","timeFrame":"Up to approximately 60 days","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}